dataesr/scientific-paragraphs-categorization huggingface dataset:
Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment Outcome or subgroup title No. of studies No. of partici- pants Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Outcome or subgroup title No. of studies No. of partici- Statistical method Effect size pants 6. 1 FDCs only at intensive phase 1 271 Risk Ratio (M-H, Random, 95% 1. 84 [0. 55, 6. 15] CI) 6. 2 FDCs during all treatment 12 5259 Risk Ratio (M-H, Random, 95% 0. 87 [0. 48, 1. 59] CI) 7 Other adverse events 9 4639 Risk Ratio (M-H, Fixed, 95% CI) 0. 85 [0. 72, 1. 00] 7. 1 FDCs only at intensive phase 1 271 Risk Ratio (M-H, Fixed, 95% CI) 1. 05 [0. 75, 1. 48] 7. 2 FDCs during all treatment 8 4368 Risk Ratio (M-H, Fixed, 95% CI) 0.
1 Fixed-dose combinations (FDCs) only at intensive phase Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Analysis 4. 2 Teo 1999 2/154 1/153 2. 99% 1. 99[0. 18,21. 69] Subtotal (95% CI) 154 153 2. 99% 1. 99[0. 18,21. 69] Total events: 2 (FDCs), 1 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=0. 56(P=0. 57) 4. 1. 2 FDCs during all treatment Chaulet 1995 1/102 1/107 2. 91% 1. 05[0. 07,16. 55] Su 2002 0/26 0/25 Not estimable Suryanto 2008 9/236 4/198 12. 97% 1. 89[0. 59,6. 04] Bartacek 2009 22/582 19/577 56. 91% 1. 15[0. 63,2. 1] Lienhardt 2011 10/684 8/664 24. 21% 1. 21[0. 48,3. 06] Wu 2015 0/49 0/49 Not estimable Subtotal (95% CI) 1679 1620 97. 01% 1. 26[0. 8,1. 99] Total events: 42 (FDCs), 32 (SDF) Heterogeneity: Tau =0; Chi =0.
58, df=3(P=0. 9); I =0% Test for overall effect: Z=1(P=0. 32) Total (95% CI) 1833 1773 100% 1. 28[0. 82,2] Total events: 44 (FDCs), 33 (SDF) Heterogeneity: Tau =0; Chi =0. 72, df=4(P=0. 95); I =0% Test for overall effect: Z=1. 09(P=0. 28) Test for subgroup differences: Chi =0. 13, df=1 (P=0. 71), I =0% Favours FDCs 0. 005 0. 1 1 10 200 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
4. 3. Comparison 4 Fixed-dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 3 Death. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Zaka-Ur-Rehman 2008 0/141 1/69 3. 63% 0. 16[0. 01,3. 98] Suryanto 2008 11/173 18/149 34. 99% 0. 53[0. 26,1. 08] Bartacek 2009 11/558 4/564 7. 2% 2. 78[0. 89,8. 68] Lienhardt 2011 4/684 7/664 12. 85% 0. 55[0. 16,1. 89] Wu 2015 6/75 8/86 13. 48% 0. 86[0. 31,2. 37] Subtotal (95% CI) 2241 2288 89. 43% 0. 91[0. 61,1. 35] Total events: 44 (FDCs), 54 (SDF) Heterogeneity: Tau =0; Chi =11. 52, df=8(P=0. 17); I =30. 56% Test for overall effect: Z=0.
8% 2. 02[0. 19,21. 93] Zhu 1998 0/227 0/81 Not estimable Su 2002 7/57 2/48 3. 93% 2. 95[0. 64,13. 53] Favours FDCs 0. 005 0. 1 1 10 200 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total events: 2122 (FDCs), 2090 (SDF) Heterogeneity: Tau =0; Chi =15. 74, df=12(P=0. 2); I =23. 74% Test for overall effect: Z=0. 98(P=0. 33) Test for subgroup differences: Chi =0, df=1 (P=0. 97), I =0% Favours SDF 0. 5 0. 7 1 1. 5 2 Favours FDCs Analysis 4. 5.
dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI RCTAI 1989 22/102 30/108 17. 96% 0. 78[0. 48,1. 25] Chaulet 1995 0/118 3/123 2. 94% 0. 15[0. 01,2. 85] Zhang 1996 0/102 1/103 2. 57% 0. 34[0. 01,8. 17] Zhu 1998 0/258 13/90 3. 2% 0. 01[0,0. 22] Su 2002 3/57 2/48 6. 66% 1. 26[0. 22,7. 25] Munteanu 2004 0/20 0/20 Not estimable Zaka-Ur-Rehman 2008 0/194 2/99 2. 82% 0. 1[0,2. 12] Suryanto 2008 0/236 2/198 2.
dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total (95% CI) 2301 2338 100% 0. 85[0. 72,1] Total events: 235 (FDCs), 249 (SDF) Heterogeneity: Tau =0; Chi =11. 33, df=7(P=0. 13); I =38. 19% Test for overall effect: Z=1. 97(P=0. 05) Test for subgroup differences: Chi =1. 84, df=1 (P=0. 18), I =45. 62% Favours FDCs 0. 2 0. 5 1 2 5 Favours SDF Comparison 5.
Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase Cochrane Library Cochrane Library Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Outcome or subgroup title Analysis 5. 1 No. of studies No. of partici- Statistical method Effect size pants 5 Sputum smear or culture conversion at 7 2319 Risk Ratio (M-H, Fixed, 0. 99 [0. 96, 1. 02] EOT 95% CI) 5. 1 Daily medication for the whole treat- 6 1961 Risk Ratio (M-H, Fixed, 0. 99 [0. 96, 1. 02] ment 95% CI) 5. 2 Daily medication at intensive phase fol- 1 358 Risk Ratio (M-H, Fixed, 1. 00 [0. 95, 1. 05] lowed by intermittent treatment at contin- 95% CI) uation phase 6 Acquisition of drug resistance 3 491 Risk Ratio (M-H, Fixed, 0.
dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Teo 1999 11/121 3/130 2. 93% 3. 94[1. 13,13. 78] Suryanto 2008 10/99 2/73 2. 33% 3. 69[0. 83,16. 32] Lienhardt 2011 26/684 21/664 21. 57% 1. 2[0. 68,2. 11] Subtotal (95% CI) 904 867 26. 83% 1. 72[1. 07,2. 75] Total events: 47 (FDCs), 26 (SDF) Heterogeneity: Tau =0; Chi =4. 23, df=2(P=0. 12); I =52. 75% Test for overall effect: Z=2. 24(P=0.
dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI 5. 8.
2 Daily medication at intensive phase followed by intermittent treatment at continuation phase Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Test for subgroup differences: Chi =0. 02, df=1 (P=0. 9), I =0% Favours FDCs 0. 2 0. 5 1 2 5 Favours SDF Comparison 6. Teo 1999 45/132 45/139 17. 22% 1. 05[0. 75,1. 48] Munteanu 2004 0/20 0/20 Not estimable Lienhardt 2011 11/797 22/784 8. 71% 0. 49[0. 24,1. 01] Subtotal (95% CI) 949 943 25. 93% 0. 86[0. 64,1. 18] Total events: 56 (FDCs), 67 (SDF) Heterogeneity: Tau =0; Chi =3. 69, df=1(P=0. 05); I =72. 89% Test for overall effect: Z=0. 93(P=0. 35) Total (95% CI) 2301 2338 100% 0. 85[0. 72,1] Total events: 235 (FDCs), 249 (SDF) Heterogeneity: Tau =0; Chi =11.
Supervised treatment versus self-administered treatment during the intensive phase Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Outcome or subgroup title No. of studies No. of partici- Statistical method Effect size pants 6 Treatment adherence at 8 weeks of 3 881 Risk Ratio (M-H, Random, 1. 04 [0. 96, 1. 12] starting treatment 95% CI) 6. 1 Supervised treatment during the 1 142 Risk Ratio (M-H, Random, 1. 01 [0. 97, 1. 06] intensive phase 95% CI) 6. 2 Self-administered treatment during 2 739 Risk Ratio (M-H, Random, 1. 09 [0. 90, 1. 31] Outcome or subgroup title the intensive phase No. of studies No. of partici- Statistical method 95% CI) Effect size pants 7 Treatment adherence at EOT 5 1229 Risk Ratio (M-H, Fixed, 95% 1. 01 [0.
1 Supervised treatment during the intensive phase Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Chaulet 1995 1/102 1/107 6. 76% 1. 05[0. 07,16. 55] Teo 1999 2/154 1/153 6. 94% 1. 99[0. 18,21. 69] Lienhardt 2011 10/684 8/664 56. 19% 1. 21[0. 48,3. 06] Wu 2015 0/49 0/49 Not estimable Subtotal (95% CI) 989 973 69. 89% 1. 27[0. 56,2. 89] Total events: 13 (FDCs), 10 (SDF) Heterogeneity: Tau =0; Chi =0. 16, df=2(P=0. 92); I =0% Test for overall effect: Z=0. 58(P=0. 56) 6. 1. 2 Self-administered treatment during the intensive phase Su 2002 0/26 0/25 Not estimable Suryanto 2008 9/236 4/198 30. 11% 1. 89[0. 59,6. 04] Subtotal (95% CI) 262 223 30.
11% 1. 89[0. 59,6. 04] Total events: 9 (FDCs), 4 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=1. 07(P=0. 28) Total (95% CI) 1251 1196 100% 1. 46[0. 75,2. 84] Total events: 22 (FDCs), 14 (SDF) Heterogeneity: Tau =0; Chi =0. 46, df=3(P=0. 93); I =0% Test for overall effect: Z=1. 11(P=0. 27) Test for subgroup differences: Chi =0. 29, df=1 (P=0. 59), I =0% Favours FDCs 0. 05 0. 2 1 5 20 Favours SDF Analysis 6. 2 Favours FDCs 0. 05 0. 2 1 5 20 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
1 Supervised treatment during the intensive phase Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total (95% CI) 1387 1289 100% 1. 69[1. 09,2. 63] Total events: 52 (FDCs), 29 (SDF) Heterogeneity: Tau =0; Chi =4. 84, df=6(P=0. 56); I =0% Test for overall effect: Z=2. 33(P=0. 02) Test for subgroup differences: Chi =1. 01, df=1 (P=0. 31), I =1. 14% Favours FDCs 0. 2 0. 5 1 2 5 Favours SDF Analysis 6. 3. Chaulet 1995 1/102 0/107 1. 6% 3. 15[0. 13,76. 34] Zhang 1996 2/101 2/101 6. 57% 1[0. 14,6. 96] Teo 1999 11/121 3/130 9. 5% 3. 94[1. 13,13. 78] Zaka-Ur-Rehman 2008 0/141 0/69 Not estimable Lienhardt 2011 26/684 21/664 69. 98% 1. 2[0.
82[0. 55,1. 22] Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Suryanto 2008 188/198 152/160 31. 87% 1[0. 95,1. 05] Wu 2015 49/49 49/49 9. 38% 1[0. 96,1. 04] Subtotal (95% CI) 339 308 58. 87% 1[0. 97,1. 03] Total events: 326 (FDCs), 297 (SDF) Heterogeneity: Tau =0; Chi =0. 59, df=3(P=0. 9); I =0% Test for overall effect: Z=0. 07(P=0. 95) Total (95% CI) 668 492 100% 1[0. 98,1. 03] Total events: 651 (FDCs), 477 (SDF) Heterogeneity: Tau =0; Chi =0. 99, df=5(P=0. 96); I =0% Test for overall effect: Z=0. 35(P=0. 72) Test for subgroup differences: Chi =0. 33, df=1 (P=0. 56), I =0% Favours SDF 1 1 1 Favours FDCs Analysis 6. 6 Total events: 41 (FDCs), 56 (SDF) Heterogeneity: Tau =0; Chi =8.
1 Supervised treatment during the intensive phase Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Chaulet 1995 44/44 50/52 11. 38% 1. 04[0. 97,1. 11] Subtotal (95% CI) 44 52 11. 38% 1. 04[0. 97,1. 11] Total events: 44 (FDCs), 50 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=1. 08(P=0. 28) 6. 7. 2 Self-administered treatment during the intensive phase Geiter 1987 118/122 408/416 45. 39% 0. 99[0. 95,1. 02] RCTAI 1989 35/95 37/101 8. 8% 1. 01[0. 7,1. 45] Zhu 1998 247/258 83/90 30. 19% 1. 04[0. 97,1. 11] Su 2002 18/26 17/25 4. 25% 1. 02[0. 7,1. 48] Subtotal (95% CI) 501 632 88. 62% 1. 01[0. 96,1. 06] Total events: 418 (FDCs), 545 (SDF) Heterogeneity: Tau =0; Chi =2.
21, df=3(P=0. 53); I =0% Test for overall effect: Z=0. 29(P=0. 77) Total (95% CI) 545 684 100% 1. 01[0. 97,1. 06] Total events: 462 (FDCs), 595 (SDF) Heterogeneity: Tau =0; Chi =3. 1, df=4(P=0. 54); I =0% Test for overall effect: Z=0. 47(P=0. 64) Test for subgroup differences: Chi =0. 49, df=1 (P=0. 49), I =0% Favours SDF 1 1 1 Favours FDCs Analysis 6. 8. Favours SDF 1 1 1 Favours FDCs Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
99[0. 4,2. 44] Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Test for subgroup differences: Chi =0. 48, df=1 (P=0. 49), I =0% Favours FDCs 0. 01 0. 1 1 10 100 Favours SDF Analysis 6. 9. Total events: 8 (FDCs), 8 (SDF) Heterogeneity: Tau =0; Chi =2. 41, df=2(P=0. 3); I =16. 91% Test for overall effect: Z=0. 03(P=0. 98) 6. 8. 2 Self-administered treatment during the intensive phase RCTAI 1989 1/102 0/108 5. 22% 3. 17[0. 13,77. 05] Subtotal (95% CI) 102 108 5. 22% 3. 17[0. 13,77. 05] Total events: 1 (FDCs), 0 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=0. 71(P=0. 48) Total (95% CI) 1177 1089 100% 1. 1[0. 46,2. 6] Total events: 9 (FDCs), 8 (SDF) Heterogeneity: Tau =0; Chi =2.
86, df=3(P=0. 41); I =0% Test for overall effect: Z=0. 22(P=0. 83) Favours FDCs 0. 01 0. 1 1 10 100 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
10. Comparison 6 Supervised treatment versus self-administered treatment during the intensive phase, Outcome 10 Other adverse events. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Zhu 1998 23/258 8/90 6. 94% 1[0. 47,2. 16] Teo 1999 45/132 45/139 25. 63% 1. 05[0. 75,1. 48] Munteanu 2004 0/20 0/20 Not estimable Zaka-Ur-Rehman 2008 40/194 26/99 20. 13% 0. 79[0. 51,1. 21] Lienhardt 2011 11/797 22/784 12. 97% 0. 49[0. 24,1. 01] Subtotal (95% CI) 1621 1358 97. 88% 0. 79[0. 64,0. 96] Total events: 154 (FDCs), 157 (SDF) Heterogeneity: Tau =0; Chi =6. 63, df=5(P=0. 25); I =24. 53% Test for overall effect: Z=2. 35(P=0. 02) 6. 10. 2 Self-administered treatment during the intensive phase Geiter 1987 6/122 8/416 2.
Trials with four drugs as fixed-dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase Outcome or subgroup title No. of studies No. of partici- pants Statistical method Effect size Cochrane Library Cochrane Library Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Outcome or subgroup title Outcome or subgroup title No. of studies No. of studies No. of partici-No. of partici- Statistical method Statistical method Effect size Effect size pants pants 3. 1 Four drugs as FDCs during the in-9. 1 Four drugs as FDCs during the in- 4 3 3002 2996 Risk Ratio (M-H, Fixed, 95% Risk Ratio (M-H, Fixed, 95% 0. 79 [0. 48, 1. 30] 0.
1 Four drugs as FDCs during the intensive phase Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Lienhardt 2011 26/684 21/664 21. 57% 1. 2[0. 68,2. 11] Subtotal (95% CI) 1392 1283 93. 08% 1. 18[0. 91,1. 54] Total events: 110 (FDCs), 92 (SDF) Heterogeneity: Tau =0; Chi =2. 51, df=2(P=0. 29); I =20. 28% Test for overall effect: Z=1. 26(P=0. 21) 7. 2. Zaka-Ur-Rehman 2008 0/141 0/69 Not estimable Suryanto 2008 10/99 2/73 2. 33% 3. 69[0. 83,16. 32] Bartacek 2009 74/468 69/477 69. 18% 1. 09[0.
2 Three or 2 drugs as FDCs during the intensive phase Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Heterogeneity: Tau =0; Chi =3. 59, df=5(P=0. 61); I =0% Test for overall effect: Z=0. 68(P=0. 5) Total (95% CI) 2373 2427 100% 0. 96[0. 67,1. 39] Total events: 52 (FDCs), 60 (SDF) Heterogeneity: Tau =0; Chi =12. 21, df=9(P=0. 2); I =26. 27% Test for overall effect: Z=0. 21(P=0. 84) Test for subgroup differences: Chi =1. 29, df=1 (P=0. 26), I =22. 74% Favours FDCs 0. 005 0. 1 1 10 200 Favours SDF Analysis 7.
81[0. 37,1. 77] Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total events: 2 (FDCs), 3 (SDF) Heterogeneity: Tau =0; Chi =0. 33, df=2(P=0. 85); I =0% Test for overall effect: Z=0. 34(P=0. 74) Test for subgroup differences: Chi =0. 09, df=1 (P=0. 76), I =0% Favours FDCs 0. 001 0. 1 1 10 1000 Favours SDF Analysis 7. 7. Total events: 48 (FDCs), 83 (SDF) Heterogeneity: Tau =0. 58; Chi =19. 23, df=7(P=0. 01); I =63. 6% Test for overall effect: Z=0. 52(P=0. 6) Total (95% CI) 2760 2770 100% 0.
1 Four drugs as FDCs during the intensive phase Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total events: 109 (FDCs), 117 (SDF) Heterogeneity: Tau =0; Chi =8. 51, df=4(P=0. 07); I =52. 97% Test for overall effect: Z=0. 9(P=0. 37) Total (95% CI) 2301 2338 100% 0. 85[0. 72,1] Total events: 235 (FDCs), 249 (SDF) Heterogeneity: Tau =0; Chi =11. 33, df=7(P=0. 13); I =38. 19% Test for overall effect: Z=1. 97(P=0. 05) Test for subgroup differences: Chi =0. 41, df=1 (P=0. 52), I =0% Favours FDCs 0.
dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Trial Regimen Directly Dosing Dose simulation during intensive phase Comment treatment observed therapy 45 kg participant 60 kg participant Fixed-dose Single-dose Fixed-dose Single-dose Bartacek 2HRZE/4HR Mode of By weight Unclear Unclear Unclear Unclear The trial authors state: "The mean daily dos- 2009 drugs ad- categories es of INH, PZA and EMB administered during ministra- the initiation phase in the 4-FDC group were tion: not re- significantly lower than those administered in ported the ST group; RMP doses were similar in both groups". Chaulet 2HRZ/4HR At the be- By weight H: 250 mg H: 300 mg H: 300 mg H: 300 mg During directly observed treatment (DOT), 1995 ginning of intensive categories R: 600 mg R: 450 mg R: 720 mg R: 600 mg "health personal" supervised treatment.
Inclusion criteria were age over 18 years, signed informed consent, fasting blood sampling, and presence of appropriate echocardiographic data. Exclusion criteria included presence of acute or chronic heart failure, any form of cardiomyopathy (e. g. , familial obstructive hypertrophic cardiomyopathy, dilated cardiomyopathy, or toxic cardiomyopathy), myocardial necrosis, heart rhythm problems, active smoking, or smoking cessation in the past 3 years, hemoglobinopathies, septicemia, hepatitis, or kidney failure requiring dialysis. All subjects underwent a complete cardiac evaluation, including medical history, physical examination, blood pressure measurement, and echocardiography. This research protocol was registered in a clinical database (ClinicalTrials. gov NCT01024049) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
The Zg-spectrum and CPMG spin-echo sequence (cpmg-spectrum) had an echo loop time (2 np) of 320 milliseconds. A total of 64 transients were sampled with a spectral width of 12 ppm, 32 K data point on time domain (2. 3 seconds acquisition time) and 2. 5 seconds additional relaxation delay. Spectra of aqueous and organic fractions were serially acquired using an automatic sampling changer (B-ACS 60). Spectra of aqueous fractions (Aq. spectrum) were obtained with similar parameters to the one-pulse spectrum of the diluted plasma whereas spectra of the organic fraction (Org. spectrum) were acquired with an additional delay of 4 seconds and without solvent suppression. 1  H NMR spectra were processed using the TOPSPIN (version 2. 1, Bruker BioSpin SA, France, Wissembourg) and AMIX (Bruker Analytik, Rheinstetten, Germany) software packages.
Typical processing parameters were 65 K zero-filling and an exponential apodizing function (0. 3 Hz) applied before Fourier transformation. Phase and base-line corrections of spectra were performed by operator and referenced with AMIX software to methyl resonance of TMPS, lactate or TCB for diluted plasma, aqueous fraction, and organic fraction, respectively. 1 H NMR spectra were processed using the TOPSPIN (version 2. 1, Bruker BioSpin SA) and AMIX (Bruker Analytik) software packages. To perform data reduction and pattern recognition, each of the 4 NMR spectra obtained per patient were bucketed to obtain spectral data sets using the AMIX (Bruker Analytik) software package. The generated variables were identified with the central chemical shift value of the bins as suffix and Zg, cpmg, Aq, or Org as prefixes.